Crossmark

Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma

Crossref DOI link: https://doi.org/10.1038/s41409-018-0142-4

Published Online: 2018-03-07

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bryant, Adam R

Perales, Miguel-Angel

Tamari, Roni

Peled, Jonathan U

Giralt, Sergio
License Information

Text and Data Mining valid from 2018-03-07
More Information

Article History

Received: 7 January 2018

Revised: 29 January 2018

Accepted: 7 February 2018

First Online: 7 March 2018

Compliance with ethical standards

:

: M.-A.P. has received consulting fees from Merck, Incyte, and Seattle Genetics, and research support from Incyte. J.U.P. has received research support and licensing fees from Seres Therapeutics. The remaining authors declare that they have no conflict of interest.